Blockage of IGF-1R signaling sensitizes urinary bladder cancer cells to mitomycin-mediated cytotoxicity

Cell Research

Volumn 11, Issue 2, 2001, Pages 107-115

  Sun, Hong Zhi ^a   Wu, Shu Fang ^b   Tu, Zeng Hong ^b  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Apoptosis; Autocrine; Drug resistance; IGF 1R signaling; Transitional cell carcinoma

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; ANTISENSE OLIGODEOXYNUCLEOTIDE; CYTOTOXIN; MESSENGER RNA; MITOMYCIN; PROTEIN SYNTHESIS INHIBITOR; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; BIOSYNTHESIS; BLADDER TUMOR; CELL CULTURE; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; ELECTRON MICROSCOPY; GENE EXPRESSION REGULATION; GENE TARGETING; GENETICS; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA; ULTRASTRUCTURE;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; AUTOCRINE COMMUNICATION; CARCINOMA, TRANSITIONAL CELL; CELL DIVISION; CYTOTOXINS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TARGETING; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MICROSCOPY, ELECTRON; MITOMYCIN; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PROTEIN SYNTHESIS INHIBITORS; RECEPTOR, IGF TYPE 1; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 0035377756     PISSN: 10010602     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cr.7290075     Document Type: Article

References (35)

1. Davies JM, Occupational and environmental factors in bladder cancer. In Scientific Foundation of Urology, Heinemanm London, Indedn 1992:723-7.
2. Bindels M, Vermey M, Rebel J.M, Zwarthoff EC, Van-Der-Kwast TH. In vitro modulation of implantation and intraepithelial expansion of bladder tumor cells by epidermal growth factor. Exp Cell Res 1997; 235:395-402.
3. Nakagawa M, Emoto A, Nasu N, Nomura Y. Clinical significance of multi-drug resistance associated protein and P-glycoprotein in patients with bladder cancer. The Journal of Urology 1997; 157:1260-5.
4. Borsellino N, Nonavida B, Ciliberto G, Toniatti C, Travail S, D'Alessandro N. Blocking signaling through the GP130 receptor chain by interleukin-6 and oncostatin inhibits PC-3 cell growth and sensitizes the tumor cells to Etoposide and cisplatin-mediated cytotoxicity. Cancer 1999; 85:134-44.
5. Dunn SE, Hardman RA, Kari FW, Insulin-like growth factor (IGF-1) alters drug sensitivity of HBL100 human-breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res 1997; 57:2687-93.
6. Torrisi R, Mezzetti M, Johannson H, Decensi A. Time course of fenretinide-induced modulation of circulating insulin-like growth factor 1, IGF-2 and IGFBP in a bladder cancer chemoprevention trial. Int C Cancer 2000; 87:601-5.
7. Blakesley VA, Stannard BS, Kalebic T, Helman LJ, Roith D. Role of IGF-1 receptor in mutagenesis and tumor promotion. Journal of Endocrinology 1997; 152:339-44.
8. Baserga R, Hongo A, Rubini M, Pvisco M, Valentinis B. The IGF-1 receptor in cell growth, transformation and apoptosis. Biochimica et Biophysica Acta 1997; 1332:F105-26.
9. Baserga R. The IGF-1 receptor in cancer research. Experimental Cell Research 1999; 253:1-6.
10. Alessandro ND. Biology versus pharmacology in drug resistance. Oncol Rep 1997; Supple:207-10.
11. Xu F, Garder A, Tu Y. Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors. Bri-J-Haematol 1997; 97:429-40.
12. Singleton JR, Dixit VM, Feldman EL. Typel insulin-like growth factor receptor activation regulates apoptotic proteins. J Biol Chem 1996; 27:31771-4.
13. Parrizas M, LeRoith D. Insulin-like growth factor 1 inhibition of apoptosis is associated with increased expression of the bcl-XL gene product. Endocrinology 1997; 138:1355-8.
14. Anderson P. Kinase cascades regulating entry into apoptosis. Microbiology and molecular Biology Reviews 1997; 16:33-46.
15. Cote R.J, Esrig D, Groshem S. P53 and treatment of bladder cancer. Nature 1997; 385:123.
16. Fadeel B, Hassan Z, Hellstrom-Lindberg E, Henter JI, Orrenius S, Zhivotovaky B. Cleavage of Bcl-2 is an early event in chemotherapy-induced apoptosis of human myeloid leukemia cells. Leukemia 1999; 13:719-28.
17. Huo Y, Jin G, Houston CW, Thompson JC, Townsend JR. Insulin-like growth factor-1 promotes multidrug resistance in MCLM colon cancer cells. Journal of Cellular Physiology 1998; 175:141-8.
18. Iwanura M, Ishibe M, Sluss PM. Characterization of7 insulin-like growth factor 1 binding sites in human bladder cancer cells lines. Urol. Res. 1993; 21:27-32.
19. Cooper MJ, Fischer M, Komitowski D, Shevelev A, Schulze E, Ariel I. Developmentally imprinted genes as markers for bladder tumor progression. The Journal of Urology 1996; 155:2120-7.
20. Sandra ED, Frank WK, John F, Joel RL, Barrett JC. Dietary Restriction reduces insulin-like growth factor 1 levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Research 1997; 57:4667-72.
21. Hasegawa S, Abe T, Naito S, Kotoh S, Kumazawa J. Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase 2 in human multi-drug-resistant bladder cancer cell line. British Journal of Cancer 1995; 71:907-13.
22. Reznikoff CA, Johnson MD, Nobhack DH, Bryan GT. Growth and characterization of normal human urothelium in vitro. In Vitro 1983; 19:326-43.
23. Ulirich A, Gray A, Tam A. Insulin-like growth factor 1 receptor primary struture: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 1986; 5:2503-12.
24. Sussenback JS, The gene structure of the insulin-like growth factor family. Prog Growth Factor Res 1989; 1:33-8.
25. Pagter-Holthuizen PD, Van Schaik FM, Verduijn GM. Organization of the genes for insulin-like growth factor 1 and 2. FEBS lett 1986; 195:2503-12.
26. CHANG Yunchao, Xu Yonghua. Expression of Bcl-2 inhibited Fas-mediated apoptosis in human hepatocellular carcinoma BEL-7404 cells. Cell Research 2000; 10:233-42.
27. Resnicoff M, Coppola D, Sell C, Rubin R, Ferrone S. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the Type 1 insulin-like growth factor receptor. Cancer Research 1994; 54:4848-50.
28. Singh SV, Scalamogna D, Hong X, O'TooLE S, Emerson EO. Biochemical characterization of a mitomycin C resistant human bladder cancer cell line. Int J Cancer 1996; 65:852-7.
29. Ruck A, Paulie S. The epidermal growth factor receptor is involved in autocrine growth of human bladder carcinoma cell lines. Anticancer Res 1997; 17:1925-31.
30. Pow-Sang JM, Seigne JD. Contemporary Management of Superficial Bladder Cancer. Cancer Control 2000; 4:335-9.
31. Kelly JD, Williamson HP, Johnston SR. Induction of apoptosis by mitomycin-C in an ex vivo model of bladder cancer. BJU International 2000; 85:911-7
32. Ruck A, Takobson E, Bjorkman S, Paulie S. Adaptation of human bladder carcinoma cell lines to serum-free growth: Evidence for autocrine growth stimulation. Anticancer Res 1994; 14:55-60.
33. Otto T, Bex A, Schmidt U, Ral A, Rubben H. Improved prognosis assessment for patients with bladder carcinoma. Am J Pathol 1997; 150:1919-23.
34. Tanoquchi H, Tachibana M, Murai M. Autocrine growth induced by tranferrin-like substance in bladder carcinoma cells. Br J Cancer 1997; 76:1262-70.
35. Okamoto M, Hattori K, Oyasu R. Interleukin-6 function as an autocrine growth factor in human bladder carcinoma cell lines. In J Cancer 1997; 72:149-54.